维普期刊资源整合服务平台（V6.5）

198篇 您的检索式：作者名="Lasho"

选中清除导出查看参考文献查看引证文献引用追踪共10页首页上一页第1页下一页末页 /10 跳转

	题名	作者	年代	出处	被引量
1	JAK2 617F mutation in essential thrombocy thaemia: clincal associations and long-term prognostic relevance 显示文摘	WOLANSKYI A P LASHO T L SCHWAGER S M	2005	Br J Haematol2005，131，2：	1
2	MPL515 mutations in myeloproliferative and other myeloid disorders:a study of 1182patients显示文摘	Pardanani AD Levine RL Lasho T		0，，10：	1
3	IDH1 and IDH2 mutation analysis inchronic- and blast-phase my- eloproliferative neoplasms显示文摘	Pardanani A Lasho TL Finke CM	2010	Leukemia2010，24，6：	1
4	MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients显示文摘	Pardanani AD Levine RL Lasho T	2006	Blood2006，108，10：	1
5	Calreticulin mutations and long-term survival in essential thmmboeythemia 显示文摘	Tefferi A Wassie EA Lasho TL	2014	Leukemia2014，28，12：	1
6	Validation of two clinically useful assays for evaluation of JAK2V617F mutation in chronic myeloproliferative disorders显示文摘	McClure R Mai M Lasho T	2006	Leukemia2006，20，1：	1
7	The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia; lineage specificity and clinical correlates 显示文摘	TEFFERI A LASHO T L SCHWAGER S M	2005	Br J Haematol2005，131，3：	1
8	JAK2 mutation in essential thrombocythaemia: clinical associations and long- term prognostic relevance显示文摘	Wolanskyj AP Lasho TL Schwager SM	2005	Br J Haematol2005，131，2：	1
9	CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia 显示文摘	Pardanani A Lasho TL Laborde RR	2013	Leukemia2013，27，9：	1
10	CALR vsJAK2 vs MPL-mutated or triple -negative myelofibrosis: clinical, cytogenetic and molecular comparisons显示文摘	Tefferi A Lasho TL	2014	Leukemia2014，28，7：	1
11	The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and myelodysplastic syndromes显示文摘	STEENSMA D P DEWALD G W LASHO T L	2005	Blood2005，106，：	1
12	CALR vs JAK2 vs MPL- mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 显示文摘	Tefferi A Lasho TL Finke CM	2014	Leukemia2014，28，7：	1
13	CALR vs JAK2 vs MPL- mutated or triple - negative myeloflbrosis : clinical, cytogenetie andmolecular comparisons 显示文摘	Tefferi A Lasho TL Finke CM	2014	Leukemia2014，28，7：	1
14	SF3BI mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value显示文摘	Patnaik MM Lasho TL Hodnefield JM	2012	Blood2012，119，2：	1
15	Systemic mastocytosis in 342 consecutive adults:survival studies and prognostic factors显示文摘	Lim KH Tefferi A Lasho TL	2009	Blood2009，113，：	1
16	Type 1 vs type 2 calreticulinmutations in primary myelofibrosis: differences in phenotype and prognostic impact 显示文摘	Tefferi A Lasho TL Finke C	2014	Leukemia2014，28，7：	1
17	Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors显示文摘	Lim KH Tefferi A Lasho TL	2009	Blood2009，113，23：	1
18	JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm:assessment of value in a series of 664 consecutive patients显示文摘	Pardanani A Lasho TL Hussein K	2008	Mayo Clin Proc2008，83，：	1
19	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients 显示文摘	Tefferi A Guglielmelli P Lasho TL	2014	Leukemia2014，28，7：	1
20	Clinical correlates of JAK2V617Fallele burden in es-sential thrombocythemia显示文摘	KITTUR J KNUDSON R A LASHO T L	2007	Cancer2007，109，：	1

返回顶部每页显示：

共10页首页上一页第1页下一页末页 /10 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示